News

GlobalData on MSN2d
FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...
FDA approves Dupixent for bullous pemphigoid
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.
Dermatology Advisor1d
Dupixent Gains Approval for Bullous Pemphigoid
The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.
Medical Dialogues5d
FDA Approves Dupilumab as First Targeted Treatment for Bullous Pemphigoid
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...
Managed Healthcare Executive4d
FDA Approves Dupixent as First Targeted Treatment for Bullous Pemphigoid in Adults
This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...
PMLive4d
Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...
Pharmabiz6d
Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid
Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid: Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administrat ...
Wall Street Journal6d
Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease - WSJ - The Wall Street Journal
France’s Sanofi and Tarrytown, N.Y.-based Regeneron said Friday that the FDA gave the green light for Dupixent as a treatment of adult patients with bullous pemphigoid, a skin disease that ...